
Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipe... Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's. Show more
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1201 | -13.9634926171 | 0.8601 | 0.8601 | 0.6851 | 115998 | 0.7542113 | CS |
4 | -0.44 | -37.2881355932 | 1.18 | 1.19 | 0.6851 | 899157 | 0.99668311 | CS |
12 | -0.44 | -37.2881355932 | 1.18 | 1.34 | 0.6851 | 397798 | 1.03341715 | CS |
26 | -1.47 | -66.5158371041 | 2.21 | 2.25 | 0.6851 | 300994 | 1.27963856 | CS |
52 | -9.96 | -93.0841121495 | 10.7 | 15.06 | 0.6851 | 580652 | 4.40346334 | CS |
156 | -170.26 | -99.567251462 | 171 | 225 | 0.6851 | 452101 | 79.60738999 | CS |
260 | -4349.26 | -99.9829885057 | 4350 | 5032.5 | 0.6851 | 1092003 | 361.91028881 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales